Mechanism
HER2; HER3 (blocks NRG1 binding to HER3)
Assets acting on this target.
- Class
- HER2 x HER3 bispecific antibody (zenocutuzumab / Bizengri)
- Pathway
- Blocks NRG1-driven HER2:HER3 dimerization, downstream PI3K/AKT/mTOR and RAS/MAPK signaling
Mechanism
Assets acting on this target.
1 of 1 assets